Key figures

 

 

SEK million

 

2019

 

2018

 

2017

 

2016

 

2015

 

2014

Net revenues

844.8

783.1

643.7

705.9

646.2

570.3

whereof ZUBSOLV® US net revenue

719.2

621.5

485.8

481.8

416.7

228.0

Cost of goods sold

–105.6

–171.8

–164.4

–149.6

–150.2

–107.4

Operating expenses

–508.0

–515.6

–421.9

–584.4

–676.6

–487.9

EBIT

231.2

95.8

57.4

51.7

–180.6

–25.0

EBIT margin, %

27.4

12.2

8.9

7.3

–27.9

–4.4

US EBIT

350.9

198.3

73.7

21.4

–109.1

–100.4

US EBIT marginal, %

48.8

31.9

15.2

4.4

–26.2

–44.0

EBITDA

272.1

116.6

78.2

73.1

–99.9

–12.5

Earnings per share, before dilution, SEK

6.33

3.99

0.67

0.84

–6.09

–1.70

Earnings per share, after dilution, SEK

6.20

3.93

0.67

0.84

–6.09

–1.70

Cash flow from operating activities

290.9

242.0

146.6

156.2

–109.2

–487.3

Cash and cash equivalents

816.8

589.8

327.9

282.4

198.1

284.5

 

1 One of the products, Diabact, was divested when the subsidiary Kibion was sold in 2015